Dhawaan, Novo Nordisk waxay si rasmi ah u soo saartay warbixinteeda maaliyadeed ee 2022. Xogtu waxay muujinaysaa in iibka guud ee Novo Nordisk ee 2022 uu gaadhi doono 176.954 bilyan Danish krone (US $24.994 bilyan, beddelka sarifka ee lagu dhawaaqay warbixinta sannadlaha ah, oo la mid ah hoos), ilaa 26% sannadkii, faa'iidada hawlgelintu waxay gaadhi doontaa 74.809 bilyan Danish krone. (US $10.566 bilyan), 28% sannadkiiba, iyo faa'iidada saafiga ahi waxay noqonaysaa 55.525 bilyan deenishka krone (US $7.843 bilyan), oo ah 16% sannadkii. Waxqabadka waa mid aad u cajiib ah.

Halkee ayuu ka yimid waxqabadka muuqda ee Novo Nordisk? Jawaabtu waa analogga GLP-1. Dhuumaha wax soo saarka ee Novo Nordisk, alaabooyinka waxaa loo qaybin karaa afar nooc: GLP-1 analogues, insulin iyo analogues, xinjirowga dhiigga iyo hormoonnada kale ee dheef-shiid kiimikaadka, iyada oo la iibinayo 83.371 bilyan Danish krone ($ 11.176, marka laga reebo cirbadaha miisaan lumis), 52.952 bilyan Danish. krone ($7.479 bilyan), 11.706 bilyan Danish karoon ($1.653 bilyan) iyo 7.138 bilyan Danish karoon ($1.008 bilyan), siday u kala horreeyaan. Ka mid ah analogues GLP-1, iibinta Liraglutide hypoglycemic injections ayaa hoos u dhacayay sanadba sanadka ka dambeeya, halkaSemaglutidewaa mid soo jiidasho leh, iyada oo wadarta iibka ah 10.882 bilyan oo doolar sanadka 2022.